Recent developments include corporate actions to maintain Nasdaq compliance, strategic marketing initiatives, and capital raising activities.

• Haoxi Health Technology Limited announced a 1-for-25 reverse share split effective January 27, 2025 [N3].
• The company regained compliance with Nasdaq listing rules as of February 11, 2025 [N2].
• Haoxi Health Technology Limited launched a customized livestreaming agency strategy to enhance marketing solutions in the medical aesthetics sector in April 2025 [N1].
• In July 2026, the company closed a registered direct offering raising $4 million through the sale of Class A ordinary shares and pre-funded warrants to support working capital, operating expenses, capital expenditures, potential acquisitions, and business development activities [S2].

The company has demonstrated operational activity in the medical aesthetics marketing space with a recent strategic initiative to enhance livestreaming services. Strong liquidity ratios and access to capital through recent offerings provide financial flexibility. Regaining Nasdaq compliance and executing corporate actions such as reverse share splits indicate management's focus on regulatory adherence and shareholder value maintenance.

Haoxi Health Technology Ltd reported a net loss of $9.5 million for the fiscal year ended June 30, 2026, with negative earnings per share. The company operates in a competitive sector with limited disclosed differentiation. Taxation risks exist if classified as a PRC resident enterprise, potentially increasing tax burdens. The company's PFIC status requires ongoing assessment, introducing tax complexity for U.S. investors. Limited disclosure on sector and industry specifics constrains full business model clarity.

Haoxi Health Technology Ltd's moat appears to be linked to its specialized marketing solutions in the medical aesthetics sector, including a customized livestreaming agency strategy. The company's ability to maintain Nasdaq compliance and access capital markets through offerings supports operational continuity. However, detailed competitive advantages or proprietary technologies are not disclosed, limiting clarity on sustainable differentiation.

• Regulatory and Taxation Risks: The company faces potential PRC enterprise income tax obligations if deemed a PRC resident enterprise, including withholding taxes on dividends and gains for non-PRC shareholders, which could impact financial outcomes [S1].
• Financial Performance Risks: Haoxi Health Technology Ltd reported a net loss and negative earnings per share for the fiscal year ended June 30, 2026, indicating ongoing profitability challenges [S1].
• Market and Competitive Risks: Limited disclosure on competitive positioning and sector specifics restricts understanding of the company's ability to sustain market share and differentiate its offerings.

• Haoxi Health Technology Ltd is incorporated in the Cayman Islands and files SEC reports including Form 20-F and Form 6-K [S1][S2].
• The company operates in the medical aesthetics sector, providing marketing solutions including a customized livestreaming agency strategy [N1].
• Haoxi Health Technology Ltd completed a 1-for-25 reverse share split effective January 27, 2025 [N3].
• The company regained compliance with Nasdaq listing rules as of February 11, 2025 [N2].
• As of June 30, 2026, the company reported cash and cash equivalents of approximately $10.9 million and current assets of about $16.8 million, with current liabilities of approximately $3.7 million, resulting in a current ratio of 4.53 and a cash ratio of 2.95 [S1].
• For the fiscal year ended June 30, 2026, Haoxi Health Technology Ltd reported revenues of approximately $54.8 million and a net loss of about $9.5 million [S1].
• Basic and diluted earnings per share were negative $386.4 as of June 30, 2026 [S1].
• In July 2026, the company closed a registered direct offering raising gross proceeds of $4 million through the sale of Class A ordinary shares and pre-funded warrants, with proceeds intended for working capital, operating expenses, capital expenditures, potential acquisitions, and business development [S2].
• The company is subject to Cayman Islands taxation laws with no corporate income tax or withholding tax on dividends, but may be subject to PRC enterprise income tax if considered a PRC resident enterprise, with potential withholding taxes on dividends and gains for non-PRC shareholders [S1].
• Haoxi Health Technology Ltd is not currently classified as a Passive Foreign Investment Company (PFIC) but must assess this status annually, which depends on the composition of its income and assets [S1].